Isis Pharmaceuticals SVP Sells $606,750 in Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) SVP Richard Geary sold 15,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $40.45, for a total transaction of $606,750.00. Following the completion of the transaction, the senior vice president now directly owns 3,610 shares in the company, valued at approximately $146,025. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. Analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Thursday, November 7th. They now have a $33.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Isis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $36.18.
Isis Pharmaceuticals (NASDAQ:ISIS) traded up 7.61% on Wednesday, hitting $42.13. 1,890,659 shares of the company’s stock traded hands. Isis Pharmaceuticals has a 52 week low of $12.08 and a 52 week high of $42.69. The stock has a 50-day moving average of $38.56 and a 200-day moving average of $32.81. The company’s market cap is $4.890 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was up 103.4% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.52 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.